CODX vs TXT · rev $3.9M vs P/E 19, rev $13.70B
Co-Diagnostics, Inc. Common Stock (CODX) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
Latest reported TXT revenue for 2024-12-28 was $13.70B. Net income was $824.0M. Revenue was up 0.1% from 2023-12-30 to 2024-12-28. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
CODX currently screens at market cap $31.4M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the CODX and TXT stock pages for the full models.
Not investment advice.